Capivasertib(Truqap) is a targeted therapy drug mainly used for patients with specific types of breast lesions. Its indications are based on genetic test results, and the applicable population must be selected in strict accordance with clinical guidelines.

Capivasertib instructions: indications, efficacy and effects, dosage, side effects, precautions

Capivasertib combined with fulvestrant is suitable for patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast lesions.

Applicable population and genetic testing requirements

Patients need to confirm the presence of at least one mutation in the PIK3CA, AKT1 or PTEN genes through genetic testing. Such genetic changes may affect the sensitivity of the lesion to endocrine therapy, and Capivasertib enhances the therapeutic effect by inhibiting related signaling pathways.

Previous treatment background requirements

Patients need to use Capivasertib after endocrine therapy failure. Specifically, it includes: progression of at least one endocrine therapy regimen in the metastatic setting, or recurrence within 12 months after the end of adjuvant therapy. For premenopausal women, they need to receive luteinizing hormone-releasing hormone (LHRH) agonist treatment at the same time.

Clarifying the indication is the prerequisite for precision treatment. Patients need to undergo genetic testing and treatment evaluation under the guidance of a doctor. The following content will explain the mechanism of action and specific usage of Capivasertib.

Efficacy and function of Capivasertib(Truqap), usage and dosage

Capivasertib blocks the proliferation and survival signaling pathway of diseased cells by inhibiting the activity of AKT protein kinase. Its combination with fulvestrant can significantly prolong progression-free survival and improve patient prognosis.

Drug mechanism of action and clinical effect

Capivasertib targets AKT protein and inhibits the overactivation of PI3K/AKT/mTOR signaling pathway. Clinical studies have shown that combined treatment can extend the median progression-free survival to 7.2 months, which is significantly improved compared with fulvestrant alone (3.6 months). About 40% of patients have reduced lesion volume, and the disease control rate exceeds 50%.

Recommended dose and dosing regimen

The standard dose is 400 mg orally, twice a day (12 hours apart), and the drug is stopped for 3 days after taking it for 4 consecutive days, forming a cycle of "4 days of medication-3 days of rest". If the missed dose is within 4 hours, it needs to be taken again, and if it exceeds 4 hours, the dose is skipped. The generic drug produced by Laos Lucius is 160mg/200mg tablets. When used in combination with strong CYP3A inhibitors, the dose needs to be reduced to 320mg twice a day.

Standardized medication is an important guarantee for efficacy, and patients need to strictly follow the dosage regimen. The following content will explain the adverse reactions and precautions that need to be vigilant during treatment.

Side effects and precautions of Capivasertib

Capivasertib may cause multi-system adverse reactions, and the risk needs to be reduced through active monitoring and preventive measures. Regular follow-up visits and laboratory tests during treatment are very important.

Common side effects and management recommendations

Adverse reactions with an incidence rate of ≥20% include diarrhea, hyperglycemia, skin reactions (such as rash), lymphocytopenia, etc. Patients with diarrhea need to increase water intake and use antidiarrheal drugs in time; moisturizers can be used locally for skin reactions, and the drug should be discontinued in severe cases. Fasting blood sugar and glycosylated hemoglobin need to be monitored before treatment and monthly, and diabetic patients need to closely adjust the hypoglycemic regimen.

Warnings for medication in special populations

Capivasertib is contraindicated in pregnant women because it may cause fetal malformations. Women of childbearing age need to take high-efficiency contraceptive measures during treatment and within 1 month after discontinuation of medication. Lactating women should suspend breastfeeding. Patients with moderate to severe hepatic and renal insufficiency need to use the drug with caution and adjust the dose if necessary. Elderly patients do not need special dose reduction, but need to strengthen adverse reaction monitoring.

If severe hyperglycemia, dehydration or skin ulcers occur during treatment, seek medical attention immediately. The drug should be stored in a light-proof environment at 15°C-30°C and should be discarded if not used up within 45 days after opening. Patients should record medication time and physical reactions, and provide detailed feedback to the doctor during follow-up visits. Scientific management and family support can improve treatment compliance and quality of life.